CGT

868개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved868 programs
CGTLimited DatastaleMiltenyi Biotec, Inc.Phase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous))

B-Cell Lymphoma; B Acute Lymphoblastic Leukemia · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleJennifer Crombie, MDPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) Therapy Infusion)

Primary Mediastinal Large B-cell Lymphoma (PMBCL); Primary Mediastinal Large B Cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

Chimeric antigen receptor modified γδ T cells (Chimeric antigen receptor modified γδ T cells)

CAR; Malignant Tumors · CAR

#CAR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleSuzhou Immunofoco Biotechnology…Phase 1

Claudin 18.2 CAR-T (Claudin 18.2 CAR-T)

Gastric Cancer; Pancreatic Cancer · Gastric Cancer

#GastricCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShenzhen University General Hos…Preclinical

Claudin18.2 CAR-T cells (Claudin18.2 CAR-T cells)

Advanced Pancreatic Carcinoma; Advanced Gastric Carcinoma · Advanced Pancreatic Carcinoma

#AdvancedPancreaticCarcinoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital of G…Phase 1

Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells (Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells)

Stage IV Ovarian Cancer; Testis Cancer, Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 2

Commercial CAR-T (Commercial CAR-T)

Malignancy; Cancer · Malignancy

#Malignancy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleGreat Ormond Street Hospital fo…Phase 1

BE752TBTTBCAR33PBL (Cryopreserved BE CAR33 T Cells, Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL))

Relapsed Acute Myeloid Leukaemia · Relapsed Acute Myeloid Leukaemia

#RelapsedAcuteMyeloidLeukaemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleCartesian TherapeuticsPhase 3

Decartes-08 (Decartes-08)

Myasthaenia Gravis · Myasthaenia Gravis

#MyasthaeniaGravis#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleCartesian TherapeuticsPhase 1

Descartes-15 (Descartes-15)

Refractory Multiple Myeloma; Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Dual Specificity CD38 and bcma CAR-T Cells (Dual Specificity CD38 and bcma CAR-T Cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleEssen BiotechPhase 2

Dual-Target Antigen-Selected CAR-NK (Dual-Target Antigen-Selected CAR-NK)

Cancer; Breast Cancer · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Advanced Solid Tumor · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1/PD-L1 CAR-T cells (Dual-targeting VEGFR1/PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

29 / 44 pages

← PreviousNext →